Filed with ASX · · 100 pages · English
The report highlights the company's innovative product solutions and their impact on patient outcomes across various wound types. It also discusses leadership changes and the company's focus on expanding its global presence and clinical applications of its technology. The report outlines strategic priorities for the upcoming fiscal year, emphasizing growth and innovation in the medical technology sector.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Watch Polynovo's latest callPolynovo (ASX:PNV) Q4 2026 Earnings Call · Replay · Aug 25Read the transcript of Polynovo (ASX:PNV) Q4 2026 Earnings Call
ANNUAL REPORT 2026Proven Platform.Scaling for Growth.Remuneration Report (Audited)34Auditor’s Independence Declaration42Consolidated statement of comprehensive income43Consolidated statement of financial position44Consolidated statement of changes in equity45Consolidated statement of cash...
Follow Polynovo into a list and get an email when it puts out news.
Follow Polynovo